FDA Approval Sought for Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian CancerMarch 29th 2022
An application for approval has been submitted to the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.
Durvalumab Plus Chemoradiotherapy Does Not Extend PFS in Locally Advanced Cervical CancerMarch 28th 2022
The phase 3 CALLA study did not achieve its key end point of progression-free survival improvement with the addition of durvalumab to chemoradiotherapy in patients with locally advanced cervical cancer.
Atezolizumab Plus Chemoradiation Is Safe in Node+, Locally Advanced Cervical CancerMarch 23rd 2022
Findings presented during the SGO Annual Meeting show that atezolizumab given prior to concurrent chemoradiation may be safe with immune modulating activity in patients with node-positive, locally advanced cervical cancer.
Crane Explores the Options for Maintenance Therapy in Advanced Ovarian CancerMarch 22nd 2022
During a Targeted Oncology case-based roundtable event, Erin Crane, MD, MPH, discussed several phase 3 trials of new combinations for maintenance therapy of advanced ovarian cancer.
Broadening MTB’s Role Could Improve Response and Survival Rates in Women’s CancersFebruary 21st 2022
Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.
Immunotherapy Shakes Up Cervical Cancer Treatment ParadigmFebruary 17th 2022
In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.
Selinexor Significantly Prolongs PFS in Advanced/Recurrent Endometrial Cancer, Warranting sBLA SubmissionFebruary 8th 2022
Statistically significant improvement in progression-free survival has been shown with selinexor in patients with advanced or recurrent endometrial cancer, including those with wild-type p53.
Cemiplimab FDA Approval Application for Recurrent or Metastatic Cervical Cancer WithdrawnJanuary 28th 2022
Ahead of its Prescription Drug User Fee Act target action date, the supplemental biologics license application for cemiplimab as treatment of metastatic cervical cancer has been withdrawn.
Tweet Chat Recap: Westin Discusses Deciding on Initial Treatment of High-Grade Epithelial Ovarian Cancer Followed by MaintenanceJanuary 25th 2022
In an interview with Targeted Oncology, Shannon N. Westin, MD, MPH, FACOG, reviewed the recent tweet chat around a high-grade epithelial ovarian cancer case.
Immunotherapy Sparks Excitement for New Cervical Cancer TreatmentsJanuary 25th 2022
Immunotherapy has especially demonstrated broad activity in cervical cancer, fueling development in this area and providing further signs of hope for new treatment options to come into the landscape with greater efficacy and manageable safety profiles.
Cervical Cancer Awareness Month: Trials Assess New ImmunotherapiesJanuary 19th 2022
Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Paclitaxel/Carboplatin Demonstrates Noninferiority to Paclitaxel/Ifosfamide in Uterine CarcinosarcomaJanuary 14th 2022
Phase 3 study findings show that paclitaxel combined carboplatin stands up to the combination of paclitaxel and ifosfamide for the treatment of patients with uterine carcinosarcoma.
Balstilimab With Zalifrelimab Elicits High, Durable Responses in Recurrent/Metastatic Cervical CancerJanuary 13th 2022
In patients with recurrent and/or metastatic cervical cancer, the second-line combination of balstilimab and zalifrelimab may offer meaningful clinical benefit, but further research is needed.
SITC 2021 Updates for Cervical Cancer: AGEN1181December 17th 2021
David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.
PR-Driven Approaches to Treating Granulosa Cell TumorsOctober 16th 2021
Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.